摘要: Irinotecan (CPT-11 [Camptosar]) is currently approved for use as a second-line agent in the treatment of metastatic colorectal cancer. Phase II studies have also shown substantial single-agent activity irinotecan
cancernetwork.com参考文章(23)
O S Selawry, F M Muggia, M H Cohen, P J Creaven, H H Hansen, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer chemotherapy reports. ,vol. 56, pp. 515- 521 ,(1972)
D Gandia, D Abigerges, J P Armand, G Chabot, L Da Costa, M De Forni, A Mathieu-Boue, P Herait, CPT-11-induced cholinergic effects in cancer patients. Journal of Clinical Oncology. ,vol. 11, pp. 196- 197 ,(1993) , 10.1200/JCO.1993.11.1.196
Barbara G. Lubejko, Louise B. Grochow, David S. Ettinger, Susan E. Sartorius, Ross C. Donehower, Eric K. Rowinsky, Michael K. Rock, Tian-Ling Chen, Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks Cancer Research. ,vol. 54, pp. 427- 436 ,(1994)
Y H Hsiang, R Hertzberg, S Hecht, L F Liu, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry. ,vol. 260, pp. 14873- 14878 ,(1985) , 10.1016/S0021-9258(17)38654-4
Michelle G. Lihou, Yaw-Huei Hsiang, Leroy F. Liu, Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin Cancer Research. ,vol. 49, pp. 5077- 5082 ,(1989)
Teruo Yokokura, Tadashi Miyasaka, Hiroyasu Baba, Kazuo Nitta, Siego Sawada, Masahiko Mutai, Mieko Takeuchi, Tomiko Tanaka, Nobuaki Uehara, Takehiko Kunimoto, Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Research. ,vol. 47, pp. 5944- 5947 ,(1987)
C G Leichman, H J Lenz, L Leichman, K Danenberg, J Baranda, S Groshen, W Boswell, R Metzger, M Tan, P V Danenberg, Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. Journal of Clinical Oncology. ,vol. 15, pp. 3223- 3229 ,(1997) , 10.1200/JCO.1997.15.10.3223
P Rougier, R Bugat, J Y Douillard, S Culine, E Suc, P Brunet, Y Becouarn, M Ychou, M Marty, J M Extra, J Bonneterre, A Adenis, J F Seitz, G Ganem, M Namer, T Conroy, S Negrier, Y Merrouche, F Burki, M Mousseau, P Herait, M Mahjoubi, Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of Clinical Oncology. ,vol. 15, pp. 251- 260 ,(1997) , 10.1200/JCO.1997.15.1.251
M L Rothenberg, J R Eckardt, J G Kuhn, H A Burris, J Nelson, S G Hilsenbeck, G I Rodriguez, A M Thurman, L S Smith, S G Eckhardt, G R Weiss, G L Elfring, D A Rinaldi, L J Schaaf, D D Von Hoff, Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1128- 1135 ,(1996) , 10.1200/JCO.1996.14.4.1128
T R Buroker, M J O'Connell, H S Wieand, J E Krook, J B Gerstner, J A Mailliard, P L Schaefer, R Levitt, C G Kardinal, D H Gesme, Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 14- 20 ,(1994) , 10.1200/JCO.1994.12.1.14